Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A

Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A Discovery of novel pyrrole derivatives as potent agonists for the niacin receptor GPR109A Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a) Discovery of coumarin-dihydroquinazolinone analogs as niacin receptor 1 agonist with in-vivo anti-obesity efficacy Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate Discovery of Biaryl Anthranilides as Full Agonists for the High Affinity Niacin Receptor Discovery of Novel Tricyclic Full Agonists for the G-Protein-Coupled Niacin Receptor 109A with Minimized Flushing in Rats 5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b